FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 82136

News■ Unclear/unknown

Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with High-Risk Neuroblastoma

Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with…
EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A small private biotech grant does not affect listed equities or sector fundamentals.

Private biotech grant, no listed impact
CATALYST TO WATCH

Future IND filing, private company only

MAIN RISK

Company is not publicly traded

FULL DISPATCH

National Cancer Institute (NCI) Small Business Innovation Research (SBIR) award funds development of ET501 toward an Investigational New Drug application ATLANTA, Oct. 15, 2026 /PRNewswire/ -- Expression Therapeutics, Inc., a clinical-stage gene and cell therapy company, today announced...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-15 13:05 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.